Biological ActivityPACAP 6-38 is a potent and competitive pituitary adenylate cyclase-activating polypeptide receptor (PAC)1 antagonist (IC50 = 2 nM). Inhibits PACAP(1-27)-induced stimulation of adenylate cyclase (Ki = 1.5 nM). Antitumor activity in vivo.
(Modifications: Lys-33 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
PACAP(6-38) inhibits growth of prostate cancer cells.
Leyton et al.
Cancer Lett., 1998;125:131
The neuropeptide PACAP promotes a-secretase pathway for processing Alzheimer amyloid precursor protein.
Kojro et al.
FASEB J., 2006;20:512
Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist.
Robberecht et al.
Citation for PACAP 6-38
The citations listed below are publications that use Tocris products. Selected citations for PACAP 6-38 include:
1 Citation: Showing 1 - 1
PACAP and VIP Inhibit the Invasiveness of Glioblastoma Cells Exposed to Hypoxia through the Regulation of HIFs and EGFR Expression.
Authors: Maugeri Et al.
Proc Natl Acad Sci U S A 2016;7:139
No product specific FAQs exist for this product, however you mayView all Peptide FAQs
VersaClone cDNA Plasmids
Reviews for PACAP 6-38
There are currently no reviews for this product. Be the first to review PACAP 6-38 and earn rewards!
Have you used PACAP 6-38?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image